Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06044090 · ClinicalTrials.gov registry record · Phase 4

Brain and Stress Study

A Phase 4 study, sponsored by University of North Carolina, Chapel Hill.

Completed
Registry status
Phase 4
Development phase
10
Enrollment target

NCT06044090 is a Phase 4 study that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 10 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06044090, a Phase 4 study, has completed, sponsored by University of North Carolina, Chapel Hill.

COMPLETED
Registry status
Phase 4
Development phase
10 participants
Enrollment target

Study Summary

Motivational deficits such as anhedonia are core to several psychiatric disorders and underlie significant functional impairment. This double-blind, placebo-controlled crossover trial of minocycline, an anti-\[neuro\]inflammatory agent, examines links between chronic stress and responses to a reward-related motivation task. It will evaluate the effects of pharmacologically attenuating neuroinflammation on behavioral responses to a reward-related motivation task in individuals experiencing unemployment. Understanding the effects of neuroinflammation on reward function among individuals experiencing chronic stress represents a critical first step in identifying novel neuroimmune targets for future clinical trials.

Interventions

  • DRUG Placebo
  • DRUG Minocycline

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2022-09-12
Est. Completion 2023-12-19
Phase Phase 4

What the Registry Record Tells You About NCT06044090

The ClinicalTrials.gov registry entry for NCT06044090 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of North Carolina, Chapel Hill, which has 1,109 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT06044090 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT06044090 about?

NCT06044090 is a clinical study titled "Brain and Stress Study". Motivational deficits such as anhedonia are core to several psychiatric disorders and underlie significant functional impairment. This double-blind, placebo-controlled crossover trial of minocycline, an anti-\[neuro\]inflammatory agent, examines links between chronic stress and responses to a reward...

What is the current status of trial NCT06044090?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 10 participants. The study started on 2022-09-12. Estimated completion is 2023-12-19.

What interventions are being tested in trial NCT06044090?

The interventions under investigation include: Placebo (DRUG), Minocycline (DRUG).

Who is sponsoring clinical trial NCT06044090?

This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.